Alcresta Therapeutics is dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company strives to develop products that change nutritional care, which may be important in managing health.

The company's proprietary technology platform supports products with an initial focus on pancreatic insufficiency, which results in malabsorption common in cystic fibrosis, digestive cancers, and other serious diseases.

Alcresta Therapeutics' platform is supported by the company's extensive experience in pharmaceutical, medical device, and nutritional product development.